Meeting the UK demand for COVID19/SARS-CoV-2 vaccines via integrated manufacturing and supply chain optimisation

鉴于全球摆脱当前新冠肺炎大流行的策略依赖于通过大规模接种疫苗来发展群体免疫力，迫切需要制定一个以前所未有的规模快速生产和分销疫苗的路线图。我们寻求资金，以制定一个蓝图，根据分层疫苗接种战略，从一线人员开始，一直到英国普通人群的大规模疫苗接种，来增加SARS-CoV-2疫苗的生产、分配和管理。为此，我们将联合收割机工艺建模与供应链优化相结合，以确保（a）制剂和最终原料药的可用性，以及（B）生产与即时可用性同步进行，以逐步扩大人群。我们的模型将是开源和公开的，随后将扩展到描述欧洲的制造能力和疫苗接种活动。我们是UCL-Oxford VaxHub和帝国未来疫苗制造中心（FVMH）的成员，并已抢先体验詹纳研究所开发的病毒载体疫苗和Shattock集团开发的saRNA疫苗的数据。因此，我们已经开发了制造模型，并一直致力于优化和扩大战略。由于这两种技术是临床试验竞赛的全球领跑者（例如，美国的Moderna正在进行I期临床试验，NCT 04283461和德国的Curevac旨在于2020年初夏进入临床试验），我们的模型将适用于任何获得监管批准的疫苗。

With the world's exit strategy from the current Covid-19 pandemic dependent on developing herd immunity through mass vaccination, there is imminent need to develop a roadmap for vaccine rapid manufacture and distribution at unprecedented scale. We seek funding to develop a blueprint for ramping up production, distribution and administration of SARS-CoV-2 vaccines based on a stratified vaccination strategy that starts with front-line personnel all the way to mass vaccination of the general UK population. To do this, we will combine process modelling with supply-chain optimisation to ensure (a) drug product and final drug substance availability, and (b) that production goes hand-in-hand with immediate availability for progressively larger parts of the population. Our models will be open-source and publicly available, and they will subsequently be extended to describe European manufacturing capabilities and vaccination campaigns. We are members of both the UCL-Oxford VaxHub and Imperial's Future Vaccine Manufacturing Hub (FVMH) and have had early access to data for the viral vector vaccine developed by the Jenner Institute and the saRNA vaccine developed by the Shattock group. As such,we have already developed manufacturing models and have been working on optimisation and scaling up strategies. With these two technologies being the global frontrunners in the race to clinical trials (e.g. Moderna in the USA is in Phase I clinical trials, NCT04283461 and Curevac in Germany is aiming to enter clinical trials in early summer 2020), our models will be applicable to any of these vaccines that receive regulatory approval.